Podcasts about Eli Lilly

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel Skowronski, who suggested that obesity could become a solved disease within just a few generations of innovation.What does that mean for the millions of patients still fighting for access to GLP-1 medications like Zepbound, Mounjaro, and tirzepatide? And what is Lilly seeing in its pipeline that the rest of us can't?We dig into:Lilly's decision to stop disclosing its Phase 1 pipelineThe Camurus fluid crystal technology deal and what it means for long-acting GLP-1sEloralintide — Lilly's selective amylin agonist and potential dark horse in obesity medicineHow eloralintide compares to Novo Nordisk's cagrilintideWhy the future of obesity treatment is a toolbox, not a scoreboardThe access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gapsRetatrutide, quintuple agonists, and what's coming out of ADA 2026If you're on Zepbound, Wegovy, Ozempic, or any GLP-1 medication — or you're waiting for the next generation of obesity drugs — this episode is for you.

Soon-to-arrive drugs promise to address elevated Lp(a); Best natural alternatives to repel mosquitoes and ticks; When cancer treatments cause osteoporosis; Organoids and computer simulations promise to reduce the toll of live animal experimentation; Land snails and pythons yield clues for new drug development; Shortfall in doctors accelerated by early retirement as physicians cite “hassle factor.”

What happens when a successful oncologist leaves clinical practice to help develop cancer treatments on a global scale? In this episode of The Lebanese Physicians Podcast, Dr. Safi Shahda shares his journey from academic oncology to leadership roles at Eli Lilly, Intellia Therapeutics, and AstraZeneca. We discuss career transitions, pharma misconceptions, innovation, AI in drug development, mentorship, and how physicians can expand their impact beyond the bedside. #LebanesePhysiciansPodcast #PharmaCareers #Oncology #ClinicalResearch #DrugDevelopment #MedicalLeadership #PhysicianCareer #AstraZeneca #Biotech #HealthcareInnovation #ArtificialIntelligence #CancerResearch #MedicalEducation #CareerGrowth #PhysicianLife #Medicine #Subscribe #Podcast #Healthcare #clinicaltrials ⁨@thelebanesephysicianspodcast⁩   ⁨@astrazeneca⁩  On all podcast apps Website: https://thelebanesephysicianspodcast.podbean.com

Jordi Visser is a veteran macro investor with 30+ years of experience and the author of the VisserLabs Substack. In this conversation, we discuss why the stock market keeps hitting all-time highs despite bad news, why AI and biotech are more underappreciated than most people realize, how Eli Lilly's AI partnerships could transform longevity and chronic disease, and where Jordi thinks you need to position your portfolio to actually compound in an exponential world.======================Need liquidity without selling your crypto? Take out a Figure Crypto-Backed Loan, allowing you to borrow against your BTC, ETH, or SOL with 12-month terms, 8.91% interest rates, and no prepayment penalties. Or check out Democratized Prime (https://figuremarkets.co/pomp) and earn ~9% APY on real world assets, paid hourly. Unlock your crypto's potential today at Figure! https://figuremarkets.co/pomp Figure Lending LLC dba Figure (NMLS 1717824). Loans subject to approval. Crypto collateral may be liquidated. Terms apply - see full disclosures at figure.com/disclosures/======================Uphold is the easiest way to buy and sell crypto unlike any other platform allowing you to trade in just one step between any supported asset. Check them out at https://www.uphold.com/pomp/ This video includes a paid sponsorship with Uphold. I'm compensated by Uphold for promoting its products and services and may receive commissions from referrals. Terms apply. Not available in all jurisdictions. Digital assets are risky and may result in the total loss of your capital.======================Arch Public is an agentic trading platform that automates the buying and selling of your preferred crypto strategies. Sign up today at https://www.archpublic.com and start your automated trading strategy for free. No catch. No hidden fees. Just smarter trading.======================0:00 - Intro0:35 - Why markets keep hitting all-time highs despite bad news10:30 - Consumer confidence, savings rate & what it means16:02 - Running the economy hot — who wins and who loses19:30 - AI + biotech: why Eli Lilly is the sleeper story31:27 - How AI will improve education, finance & health38:48 - Why your wealth manager may be failing you in the exponential era

DeepSeek has made a permanent 75% discount on its flagship AI model, a move that accelerates the commoditization of AI and puts pressure on the entire AI infrastructure investment thesis. We examine what falling AI model prices mean for the companies building AI, buying AI, and investing in the picks-and-shovels of the AI boom.Today's Stocks & Topics: Tutor Perini Corporation (TPC), Market Wrap, Vanguard International Growth Adm (VWILX), SPDR Gold MiniShares (GLDM), Key Benchmark Numbers: Treasury Yields, Gold, Silver, Oil and Gasoline, International Business Machines Corporation (IBM), Quantum Computing Stocks, Investment Fees and Taxes, Eli Lilly and Company (LLY), Oil Prices this Summer.Our Sponsors:* Check out Anthropic and use my code Claude.ai/invest for a great deal: https://www.anthropic.com* Check out Plaud AI and use my code INVEST for a great deal: https://plaud.ai* Check out Scribe and use my code scribe.how/invest for a great deal: https://scribe.comAdvertising Inquiries: https://redcircle.com/brands

The Tim Conway Jr. Show Hour 1 (5.29) Friday is here, and Conway is ready to take the edge off! The crew kicks things off with weekend buzz talk, student love for Fridays, and the universal mission of getting through the week and into relaxation mode. But nothing kills a good buzz faster than the wrong snack — especially when Trader Joe’s candy starts giving people the runs. That’s right, the crew gets into the ultimate Friday night disaster: trying to feel loose and happy, only to have candy turn your weekend into a bathroom sprint. The show also dives into the wild fact that 60 Minutes has been on the air for 57 years, Conway hosting the massive OC Business Awards, and a possible medical breakthrough involving a new gene-editing cholesterol drug that could change how high cholesterol is treated. Then things get weird with the internet’s latest obsession: “hot rodent men.” From Timothée Chalamet-style features to Hollywood’s strangest beauty trend, the crew breaks down why rat-like is somehow now attractive. Conway also admits he likes gambling on new medicine, comparing it to carnival rides, Vegas casinos, Whiskey Pete’s, and his love for Primm Casino. Plus, he pitches a genius idea for reviving Primm with “The Oasis.” Later, the show turns serious with a Riverside apartment complex fire that displaced around 150 people, including UC Riverside students forced out during finals. And somehow, it all circles back to viral fire interviews, Michelle Dobney’s unforgettable “Not today!” moment, Elvis Presley’s legendary bathroom demise, and a Friday night reminder: protect your buzz, choose your candy wisely. Trader Joe’s candy, Friday vibes, weekend buzz, buzzkill, funny podcast, hot rodent men, Timothée Chalamet, gene editing, cholesterol drug, PCSK9, Eli Lilly, Primm Casino, Vegas stories, Riverside fire, UC Riverside, viral moments, Conway Show See omnystudio.com/listener for privacy information.

On today's The Gist Healthcare Podcast: a Texas judge dismisses a payer lawsuit against HaloMD, Eli Lilly reports strong results for its next-generation weight loss drug and new research links greater nurse responsibility to higher retention. Hosted on Acast. See acast.com/privacy for more information.

Howie and Harlan are joined by Nicholas Christakis, director of Yale's Human Nature Lab, to discuss his research on social networks, human connection, and the forces that help societies cooperate and endure. Harlan discusses promising phase 3 results for retatrutide, Eli Lilly's experimental "triple G" obesity drug; Howie provides an update on the fast-growing Ebola outbreak in the Democratic Republic of Congo. Show notes: Obesity Drugs "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" "Triple–Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial" Bariatric surgery Nicholas Christakis Human Nature Lab Nicholas Christakis: Blueprint: The Evolutionary Origins of a Good Society Free rider problem Phenotype Stephen Pinker The Enlightenment Nicholas Christakis on YouTube: For the Love of Science  Nicholas Christakis: "The Spread of Obesity in a Large Social Network Over 32 Years" Social contagion Altruism Wet lab vs. dry lab  Microbiome Communicable vs. non-communicable diseases Nicholas Christakis: "The Collective Dynamics of Smoking in a Large Social Network" Nicholas Christakis on YouTube : "Learning in a Time of War" Tymofiy Mylovanov The president of the Kyiv School of Economics, who invited Christakis to lecture in Ukraine. Ebola CDC: Ebola Disease 2026  CDC: Ebola Disease Basics  "The Ebola virus spreading in Congo is a rare species with no vaccines or treatments" Hypertension Watch last week's episode on YouTube. In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Micron has had a turnaround for the ages, going from a free cash flow negative company to a $1 trillion valuation in a little over a year. What does it tell us about the AI buildout? Plus, we get to Eli Lilly's incredible trial results, acquisition spree, and growth plans before ending with Zscaler's earnings and why the stock fell 30% today.Travis Hoium, Lou Whiteman, and Rachel Warren discuss:- Micron's trip to $1 trillion- Eli Lilly's Winning Streak- Zscaler earningsCompanies discussed: Micron (MU), Eli Lilly (LLY), Zscaler (ZS).Host: Travis HoiumGuests: Lou Whiteman, and Rachel WarrenEngineer: Austin Morgan, Bart Shannon Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement.We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode.Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

This week's episode explores the impact of Alzheimer's disease, on women in particular, and features insights from cognitive neurologist Dr. Neelum Aggarwal and personal stories from psychotherapist and author Leah Fisher, who herself has been diagnosed with Mild Cognitive Impairment with elevated Alzheimer's risk. The discussion covers risk factors, diagnosis challenges, and management strategies, emphasizing the importance of awareness and early intervention. We'd like to thank the American Medical Women's Association and Eli Lilly & Co for sponsoring this episode. Watch the convo on YouTube: https://youtu.be/nBReOsqkz7g   https://www.mymarriagesabbatical.com/ My Marriage Sabbatical: A Memoir of Solo Travel and Lasting Love Order Leah's book on Amason: https://amzn.to/4wM4IoD   (00:00) Intros & Bios (04:43) The Disparity Of Alzheimer's Amongst Women (09:33) Leah's Personal Experience (20:01) Primary Care's Role In Alzheimer's Diagnosis (28:04) Leah's Process Of Receiving Her Diagnosis (32:34) The Importance Of Communication In Diagnosis (35:00) Patient-Doctor Dynamics (39:12) What Life Looks Like For Leah Now (45:36) Management & Treatment Options (50:19) Final Thoughts Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Andrew, Ben, and Tom discuss the AI-driven expansion of the trillion-dollar club with SK Hynix, Micron, and Eli Lilly crossing the $1T market cap threshold and Nvidia leading at $5.2T, Zscaler's 21% premarket drop on prudent guidance and sales leadership departures, the longer-term cybersecurity opportunity as AI expands endpoints, and Ben's case for why we don't own Micron in size.Join our live YouTube stream Monday through Friday at 8:30 AM EST:http://www.youtube.com/@TheMorningMarketBriefingPlease see disclosures:https://www.narwhal.com/disclosure

Group Chat News is back with the hottest stories of the week. We get into fake peptides showing up in pools and locker rooms, Eli Lilly's gene therapy IV that drops cholesterol 65% for 18 months, and the wild gap between an S&P at all-time highs and consumer sentiment at all-time lows. We dig into the AI optimist vs. pessimist split, Andrew Sorkin's 1929 doomer pitch on 60 Minutes, and why the next Carnegies need to start building parks and libraries to win back public sentiment,the American fitness test, and much more

The CEO of IMAX discusses recent rumors of a potential sale of the company and box office demand over the holiday weekend. Then, we discuss the details of Eli Lilly's announcement to buy 3 vaccine makers for nearly $4 billion. Plus, as we await the SpaceX IPO, what could a potential merger with Tesla look like? We break down the benefits and drawbacks. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Andrew, Ben, and Tom discuss the reported two-phase US-Iran deal to reopen the Strait of Hormuz and dispose of enriched uranium, market reactions with oil dropping to the low $90s and the 10-year falling to 4.50%, Kevin Warsh's first comments as Fed Chair signaling reform, the WSJ piece on the vanishing equity risk premium, and Eli Lilly's VERVE-102 one-shot gene editing therapy showing up to 62% LDL cholesterol reduction in early trials as a potential challenger to Amgen's Repatha.Join our live YouTube stream Monday through Friday at 8:30 AM EST:http://www.youtube.com/@TheMorningMarketBriefingPlease see disclosures:https://www.narwhal.com/disclosure

Micron powered tech higher and the Nasdaq to a record close as investors continue to pile into the stock. Melius Research's Ben Reitzes breaks down the market action in the chips sector and his latest move upping the price target on both Apple and Dell. Our Annika Kim Constantino breaks down Eli Lilly's three new acquisitions then our Seema Mody on the speculation SpaceX and Tesla could merge into a single public company. DataTrek's Nick Colas on how the public markets are preparing for SpaceX's mega-IPO. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Market update for May 26, 2026Check out the Public app for incredible investing tools and to support the show (LINK)Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode, Zaid covers:why stocks keep ripping despite bond yields flashing warning signsThe latest on the Iran war and what it all means for oil pricesEli Lilly's $4 billion vaccine shopping spree and the next-gen weight loss drug analysts are calling "surgery in a syringe"Uber's $11.6 billion bid to take over European food delivery giant Delivery HeroWhy Micron stock could double from here, according to UBSBP's surprise move to remove its chairman over "serious" conduct concernsWhy fans are roasting Ferrari's first ever EV 

In this episode of THE MENTORS RADIO, Host Dan Hesse talks with Ambassador Randy Tobias, former Vice Chair of AT&T, and Chair and CEO of AT&T's primary operating unit, AT&T Communications. Randy left AT&T in 1993 to become Chair, President and CEO of Eli Lilly and Company. In 2003 President George W. Bush nominated him to be the founding United States Global AIDS Coordinator with the rank of Ambassador and with the charge to develop, launch and lead what became PEPFAR, a multibillion-dollar U.S. government initiative to blunt the global HIV/AIDS epidemic, first in sub-Saharan Africa and then globally. Now in its twenty-second year, PEPFAR is credited with having saved more than 26 million lives. Subsequently President Bush named Randy Administrator of USAID and concurrently the first Director of all United States Foreign Assistance with the rank of Deputy Secretary of State. Ambassador Tobias has been recognized with a long and diverse list of honors including five honorary degrees. He has served on a number of corporate and non-profit boards, and in leadership roles with numerous organizations including as chair of the boards of trustees of both Duke University and Indiana University. He is the author of two books, Put The Moose On The Table: Lessons In Leadership From A CEO's Journey Through Business And Life, and Never Daunted: A Life and Legacy of Embracing Change, a memoir published in 2025. LISTEN TO the radio broadcast live on iHeart Radio, or to “THE MENTORS RADIO” podcast any time, anywhere, on any podcast platform – subscribe here and don't miss an episode! SHOW NOTES: AMBASSADOR RANDY TOBIAS: BIO: BIO: Ambassador Randy Tobias BOOKS: Never Daunted: A Life and Legacy of Embracing Change, by Randall L. Tobias Put the Moose on the Table: Lessons in Leadership from a CEO’s Journey Though Business and Life, by Randall L. Tobias and Todd Tobias WEBSITE: Tobias Leadership Center, University of Indiana

Two retirees with the same balance can take wildly different incomes home — it's not about returns, it's about taxes.This week on Money On Tap, Ben Brayshaw and Dan Michelon unpack The Science of Retirement Income — How to Create Income Alpha: the practice of beating the market not by picking better stocks, but by keeping more of what you already have through tax-aware planning.What you'll learn:What "Income Alpha" actually means — and why it's worth 15–30% more retirement income, year after yearHow Social Security gets taxed at 0%, 50%, or 85% — and how to control which one applies to youThe Roth IRA conversion ladder: filling the 22% bracket today to avoid the 30%+ bracket laterThe lesser-known after-tax account strategy — converting future ordinary-income tax into capital-gains taxQualified Charitable Distributions (QCDs) — the single highest-leverage move for charitable retireesDonor-Advised Funds and Charitable Trusts — stacking giving with Roth conversion yearsThe hidden IRMAA Medicare tax — and the income thresholds that can cost you $1,000–$3,000 a yearThe Widow Tax Trap — the most damaging tax in retirement and how to plan around itWhy the year of a spouse's passing is the last big planning window — and what to do with itWhat 1–2 years of tax returns will tell a good planner that your investment statement never willPlus Money In The News:Weight-loss drug developers line up to tap a $150B market (Eli Lilly, Novo Nordisk, the pill-vs-shot race)Nike stock tumbles 13% to an 11-year low on China weaknessAverage tax refund up 11% from a year ago — IRS data and what it means for inflationFree resource: Email us with "Charitable Giving Booklet" in the subject and we'll send our charitable giving guide.Read the companion blog: brayshawfinancial.com/blogSchedule a free consultation: app.greminders.com/t/9f3ce72e/initialconsultaFull Money On Tap episode library: brayshawfinancial.com/money-on-tapContact UsPhone: 855-226-8551Email: info@yourmoneyontap.comOffice: 116 South River Road, Bedford, NH 03110Web: brayshawfinancial.comWhy do Americans fear running out of money more than death? A recent Allianz survey found that 61% of Americans fear running out of money in retirement more than they fear death itself. The shift reflects structural changes: pensions have largely disappeared, 401(k)s placed the risk of retirement success on individuals, life expectancy has stretched, inflation has accelerated, healthcare costs are rising, and Social Security is on track for a benefit cut. The fear is rational — and the planning response is to build a multi-source income plan rather than to hope a portfolio alone is enough.

Karl and Erum are back from SynBio Beta 2026 in San Jose,  and they brought home an Impact Award. In this special recap episode, they break down the biggest moments from the conference: Neon's audacious plan to engineer chicken eggs as bioreactors, P&G's push into bio ceramides with their Native brand, Twist Bioscience's expansion from DNA synthesis into proteins, and Anthropic's deepening footprint in pharma through its acquisition of Coefficient Bio and partnership with Eli Lilly. They cover panels on the dark proteome, engineered longevity, bio-based colors replacing synthetic dyes, programmable nutrition, and the future of alternative meat,  plus a standing-room-only session on bio-literacy featuring Drew Endy. Along the way, they share stories from the hallways, highlight emerging founders in DNA data storage and space biotech, recap Chef Pierre Thiam's fonio-fueled dinner, and reflect on why strengthening relationships across the bioeconomy matters more than ever.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) - Grow Everything Wins the SynBio Beta 2026 Impact Award(00:04:30) - Conference Highlights, Listener Meetups & Walking the Exhibit Hall(00:08:15) - Cellular Intelligence, BioBrain AI & Neon's Chicken Egg Bioreactor(00:13:00) - P&G's Bio Ceramides, Twist Bioscience & the Everyday Bio Panel(00:19:30) - Engineered Longevity: Gene Therapy, Matter Bio & Measuring Aging(00:22:30) - AI Meets Pharma: Anthropic, Eli Lilly's Tune Lab & Startup Alliances(00:29:00) - Bruce Friedrich on the Future of Alternative Meat(00:32:00) - Programming Nutrition: When Snacking Meets Medicine(00:36:15) - Bio-Literacy with Drew Endy & the Teaching Disorder(00:42:00) - Panel Recaps: Dark Proteome, Bio Colors, Enzymes & Chef Pierre ThiamLinks and Resources:Links and Resources DocumentTopics Covered:fungi pigments, bio-based colorants, fungal dyes, natural pigments, sustainable color, food colorants, synthetic dyes alternatives, antioxidant pigments, food and beverage, clean ingredientsHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠Music by: Nihilore Production by: Amplafy Media

Walmart raising the alarm bells on the consumer, as the big box retailer posts a disappointing outlook amid rising gas prices. How the oil shock is hitting shopper's wallets, and what we can expect to hear about the consumer when competitors report results next week. Plus, details on OpenAI's IPO timeline, how Spotify is raising the volume for its superfans, and Eli Lilly's heavy hitter; how the pharma giant is moving forward in the weight loss drug space with its next-gen obesity drug. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What does it really take to land a successful biotech partnership—and what makes a deal fall apart? In this episode, host Elaine Hamm, PhD, sits down with Renee Williams, PhD, MBA, Founder and Managing Partner of Williams Biotech Consulting and Independent Board Director for AGS Therapeutics. With experience across major pharma companies like Eli Lilly and Janssen, Renee shares hard-earned insights from the front lines of dealmaking. From communication missteps to finding the right partner, she explains how to navigate biotech partnerships with clarity, confidence, and strategy. In this episode, you'll learn: Why overcommunication is key to every stage of the deal process. How to identify (and avoid) red flags in strategic partnerships. What scientists need to know to transition into biotech business roles. Whether you're negotiating a licensing deal or dreaming of your first exit, this episode is packed with advice you won't want to miss. Links: Connect with Renee Williams, PhD, MBA, and check out Williams Biotech Consulting and AGS Therapeutics. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Learn more about Eli Lilly and Janssen Pharmaceutical. Connect with Ian McLachlan, BIO from the BAYOU producer. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über die neue KI-Offensive von Alphabet, robuste Zeiten für die Baumärkte und das Milliarden-Projekt von OHB. Außerdem geht es um Nvidia, Qualcomm, Amazon, Broadcom, Micron, Arm, Intel, Home Depot, Hornbach Holding, Ottobock, EQT, Uniper, Rheinmetall, SAP, Nemetschek, Atoss Software, Infineon, SMA Solar, Ströer, Eli Lilly, Novo Nordisk, Mondelēz International, Domino's Pizza, McKesson, Cencora, Cardinal Health, Vanguard FTSE All-World UCITS ETF (WKN: A1JX52), JPMorgan EUR Corporate Bond Research Enhanced Index UCITS ETF (WKN: A2N76D), Vanguard EUR Corporate Bond UCITS ETF (WKN: A143JK), VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF (WKN: A2JAHJ) und Amundi Smart Overnight Return UCITS ETF (WKN: LYX0WM). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und - ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency's two main review units also left their posts, as did the FDA chief of staff and chief AI officer. Domino effect aside, the reaction from the industry has been mostly positive, given Makary's tumultuous reign. But he might be hard to replace. If it were up to the biotech industry, former longtime oncology regulator and short-lived CDER director Richard Pazdur would take the role. For now, FDA Deputy Commissioner for Food Kyle Diamantas is in charge.Eli Lilly's David Ricks was the highest paid pharma CEO last year, but J&J's Joaquín Duato made the most relative to rank-and-file employees, with a median pay ratio of 358 to one. He was on the top of BioSpace's list last year, too, with a ratio of 293 to 1. Last month, Revolution Medicines' RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. This week, Truist Securities went so far as to nominate RevMed as “the next oncology titan,” a title currently held by Merck and its blockbuster cancer drug Keytruda. Safety continues to challenge the gene therapy space, especially in Duchenne muscular dystrophy. Late last week, REGENXBIO announced mixed results from a Phase 3 program—the gene therapy did lead to functional improvements, but two serious adverse events caused the stock to drop 37%.Finally, Amgen's rare disease drug Tavneos continues to face scrutiny. Last month, the FDA alleged that doctored data were filed to support Tavneos' initial approval. Now, it's been linked to 20 deaths in Japan.

A growing share of pharmaceutical innovation is now constrained not by scientific imagination, but by the infrastructure required to support AI at scale. In this episode of the AI in Business podcast, Thomas Fuchs, Chief AI Officer at Eli Lilly & Company, joins Matthew DeMello to explore how Lilly's new AI supercomputing platform is reshaping scientific discovery and enterprise operations. The conversation examines how large-scale computing enables more advanced models, secure and usable data environments, and faster scientific iteration across the organization. Learn how brands work with Emerj and other Emerj Media options at go.emerj.com/partner

This week on Conflict Managed we welcome Shalin Desai. Together we explore: Trying to escape vs. learning the skills to navigate difficult situations Learning and practicing The Art of Living breathing What is within our control Training your mind The role of emotions at work The connection between breath and emotions Emotional regulation: how? Taking the mental “trash” out regularly Conflict Managed is available wherever you get your podcasts and on YouTube @3pconflictrestoration   Shalin Desai is the Director of Programs for the Art of Living Foundation, one of the world's largest nonprofit organizations, whose initiatives have positively impacted over 500 million people across 180+ countries. With more than 25 years of experience teaching breathwork and meditation, Shalin is known for integrating ancient wisdom with modern leadership and well-being practices. He also serves as Chief Revenue Officer of Sri Sri Tattva, a global wellness brand offering natural and Ayurvedic products that promote holistic health through a blend of tradition and science. For over 15 years, Shalin has designed and delivered corporate leadership and wellness programs for organizations including Microsoft, Dell, Boston Consulting Group, Accenture, Salesforce, Eli Lilly and Company, and Merck & Co. His work helps leaders and teams manage stress, build resilience, and cultivate mental clarity while reconnecting with a deeper sense of purpose. Shalin is known for his Intuitive Life Scan, a breakthrough approach in which trained guides provide unbiased insights into an individual's current situation. A highly engaging speaker known for his relatable storytelling and humor, Shalin inspires audiences with practical techniques they can apply immediately to improve focus, leadership, and overall well-being. Shalin holds a degree in Supply Chain Management from the State University of New York and lives in Indianapolis with his wife and two children. Conflict Managed is produced by Third Party Workplace Conflict Restoration Services and hosted by Merry Brown.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is currently navigating a pivotal era marked by a blend of scientific innovation, regulatory shifts, and intriguing clinical trial results. A key regulatory upheaval unfolds as the FDA faces leadership changes. The recent departures of key figures from both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) underscore a period of uncertainty. With former commissioner Marty Makary stepping down, concerns arise about how these changes might affect drug approvals and regulatory guidance at such a crucial time in the industry. Turning to clinical trials, Regeneron has experienced a setback as its lag-3 inhibitor failed to surpass Merck's Keytruda in phase 3 melanoma studies. This marks Regeneron's second significant late-stage failure within a year, prompting analysts to reassess its strategic direction in oncology. In parallel, Regeneron has inked a $2.3 billion agreement with Parabilis Medicines to develop an advanced antibody-drug conjugate (ADC)-like therapy. The goal is to enhance targeting capabilities by improving binding to complex target sites, which could revolutionize ADC technology. Similarly, BioMarin's substantial investment in Inozyme's enzyme replacement therapy faced hurdles after falling short on one of two primary endpoints in a phase 3 trial for a rare genetic disorder. Such outcomes highlight the inherent risks and high stakes involved in late-stage drug development. Yet, innovation continues to drive progress. Vincentage Pharma's oral GLP-1 agonist has demonstrated a promising mean weight loss of 12.4% over a year, positioning it as a competitor to Eli Lilly's Orforglipron in the burgeoning Chinese market. This reflects the global pursuit to harness GLP-1 receptor agonists in tackling metabolic disorders and obesity. Ipsen has made strides with its long-acting neurotoxin for aesthetic applications, advancing into phase 3 trials following encouraging phase 2 results that showed significant improvements in frown lines lasting up to 24 weeks post-treatment. This progress suggests robust competition against established players like Botox. Meanwhile, Merck and Kelun-Biotech have successfully completed a phase 3 trial with their trop2-directed ADC sacituzumab tirumotecan (SAC-TMT) for endometrial cancer, achieving primary endpoints and paving the way for further regulatory submissions. Such advancements emphasize ADC technology's growing importance in oncology therapeutics. Broad industry trends reflect strategic investments, exemplified by Boston Scientific's $1.5 billion investment in Mirus and an option to acquire its transcatheter aortic valve replacement system—highlighting continued interest in high-growth medtech sectors. In another notable development, Daiichi Sankyo and AstraZeneca have reached a milestone with their ADC Enhertu, securing dual FDA approvals for early breast cancer treatment. These approvals underscore Enhertu's potential to expand treatment options for patients at an early disease stage, potentially altering standard treatment protocols. On the regulatory front, AstraZeneca has secured FDA approval for baxdrostat—an aldosterone synthase inhibitor developed through its acquisition of CinCor Pharma—demonstrating strategic investment in innovative cardiovascular therapies aligned with ambitious revenue goals. However, challenges persist as demonstrated by Amgen's Tavneos being linked to fatalities across Japan and the U.S., raising significant concerns about data integrity and pharmacovigilance. In contrast, Revolution Medicines' RAS inhibitor doubled survival rates in phase 3 pancreatic cancer trials. This breakthrough positions Revolution as an emerging leader in oncology therapeutics amidst fierce competition from companies aiming to improve drug tolerability and extend survival benefits. These narratives paint a picture of an industry poised for transformation—balancing scientific breakthroughs against regulatory challenges and financial pressures. As therapeutic modalities evolve—from oral biologics to advanced ADCs—the sector is set on course for substantial impacts on patient care and drug development pipelines. In summary, the pharmaceutical and biotech industries' focus on advancing therapeutic options through scientific innovation while navigating complex regulatory landscapes underscores an ongoing commitment to addressing unmet medical needs through new drug classes and targeted therapies. These efforts highlight trends toward personalized medicine and precision oncology that are likely to shape future trajectories in these dynamic fields.Support the show

This week, This Week in Pharmacy examines several stories shaping the business, clinical, and legal future of pharmacy practice. In TWIRx News from Pharmacy Times from Megan Maroney, PharmD, BCPP, FAAPP, focused on antidepressant use, withdrawal concerns, deprescribing, and shared decision-making. The key takeaway: patients should never stop antidepressants abruptly. Pharmacists can play a vital role in reducing stigma, educating patients, and supporting safe conversations about tapering, side effects, and long-term treatment. In health technology news, FDB research presented at the 2026 AMIA Amplify Informatics Conference found that patient-specific, risk-based medication guidance reduced pharmacy alert volume by 70% in a high-volume community pharmacy setting. The model consolidates alerts into one actionable message tied to the patient's most relevant risk, helping reduce alert fatigue and improve workflow. Finally, we review a federal court ruling in Eli Lilly's lawsuit against Houston-based Empower Pharmacy over compounded tirzepatide versions of Mounjaro and Zepbound. The judge dismissed key federal trademark and Texas unfair competition claims, while allowing other state claims to continue. Andy Crawford, with Keysource is back on TWIRx talking about the U.S. Supreme Court taking up Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., a case that could significantly affect generic drug competition. At issue is whether Hikma's marketing materials and public communications around its generic version of Amarin's fish oil-based cardiovascular drug improperly promoted a still-patented use. Hikma and the broader generic industry argue the case is about protecting “skinny label” rules, which allow generics to carve out patented indications while still bringing lower-cost medications to market. For pharmacists, the decision could influence generic availability, substitution confidence, pricing pressure, and how manufacturers communicate with providers and pharmacies. Thanks to our sponsors, CassianRx and IPC, for supporting independent pharmacy, innovation, and the future of patient-centered care.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the dynamic shifts and breakthroughs shaping this ever-evolving industry. In a significant regulatory update, the resignation of FDA Commissioner Marty Makary has stirred discussions across the pharmaceutical landscape. Over his 13-month tenure, Makary faced considerable scrutiny for his controversial decisions, including the rejection of several rare disease drugs. This leadership change at the FDA may herald a period of uncertainty as the agency searches for new direction amidst criticisms and operational challenges. The implications are vast, potentially affecting drug approval processes and public health policies, making it crucial for stakeholders to watch closely how the agency adapts to this transition. Simultaneously, Takeda's announcement to lay off 4,500 employees marks a strategic move to streamline operations and focus on core competencies. This decision reflects a broader industry trend where companies are optimizing their structures to enhance financial health in a highly competitive market. The cost savings from this restructuring are expected to be substantial, allowing Takeda to pivot towards more sustainable business models and focus on areas that promise future growth. Eli Lilly and Novo Nordisk continue to lead in drug development with their GLP-1 receptor agonists. Both companies have reported promising data on early response and long-term weight loss maintenance in patients, positioning their therapies as pivotal in treating obesity. Eli Lilly's obesity treatments Foundayo (orforglipron) and Zepbound (tirzepatide) have shown sustained weight-loss maintenance in Phase 3 trials, reinforcing their efficacy in metabolic health interventions. These developments not only highlight the intense competition in the GLP-1 space but also underscore the potential impact on addressing global obesity challenges effectively. The strategic landscape of mergers and acquisitions is also evolving with Merck KGaA's announcement to bolster its pipeline through strategic M&A activities. This move is emblematic of an industry-wide strategy where companies seek external innovation to fill pipeline gaps, ensuring sustained growth and competitiveness. In a related vein, BioMarin's $4.8 billion acquisition of Amicus Therapeutics signifies a firm commitment to addressing unmet needs in rare diseases, illustrating how consolidation can enhance capabilities in niche markets with significant potential. In vaccine development, Valneva's decision to reduce its workforce by up to 15% highlights ongoing challenges in the sector, particularly for travel-related vaccines affected by global market trends. This restructuring is indicative of the volatility faced by companies as they adapt strategies for long-term sustainability amidst shifting consumer behaviors. Pfizer's expansion into Europe with its hemophilia treatment Hympavzi marks a critical regulatory milestone, broadening its market presence and offering expanded therapeutic options for patients. This approval not only strengthens Pfizer's foothold in the hemophilia market but also exemplifies the global reach of innovative treatments. Technological integration continues to revolutionize R&D processes, as evidenced by AstraZeneca's licensing agreement with Owkin for AI capabilities. This partnership aims to harness AI-driven insights for drug discovery, showcasing how technology is reshaping traditional research methodologies and enhancing efficiency. Similarly, advancements in AI-powered diagnostics are evidenced by Boehringer Ingelheim's collaboration with Brainomix in pulmonary fibrosis imaging, reflecting broader trends towards personalized medicine through precise disease characterization. Kyverna Therapeutics is advancing in cell therapy with Support the show

Send us Fan MailThe pharmaceutical industry didn't just create a weight loss drug — it created a world in which you cannot escape it. In this episode, I trace Novo Nordisk and Eli Lilly's systematic strategy to buy the guidelines, bribe the charities, train the doctors, and lobby the politicians — and I show you exactly how they copied it from the people who gave us the opioid crisis. This isn't conspiracy theory. It's a paper trail. And once you see it, you cannot unsee it. Pre-order your copy of No Weigh! hereGot a question for the next podcast? Let me know!Connect With MeWEEKLY NEWSLETTER: Get a free script when you sign upTHE WEIGHTING ROOM: Community with a neurodivergent flavour. **BOOK CLUB** exclusive to Weighting Room members. CONSULTATION: For the ultimate transformation in your healthcare journeyMASTERCLASS LIBRARY: Become an expert in your condition and the weight inclusive ways to manage itFREE GUIDES:Evidence-based, not diet nonsenseFind me on Instagram, YouTube, and LinkedIn.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant shifts and advancements shaping our industry. Kicking off with a notable change in leadership, the resignation of FDA Commissioner Marty Makary signals an important realignment within the U.S. regulatory landscape. As the FDA grapples with complex challenges in drug approval and public health policy, this transition may influence future regulatory strategies. Makary's departure follows speculation about political tensions, with reports suggesting former President Trump considered his dismissal. Taking over as interim leader is Deputy Commissioner for Food Kyle Diamantas, whose expertise in food regulation might redirect the agency's approach toward drug approvals. This shift comes at a pivotal time as the FDA emphasizes real-world evidence and adaptive trial designs to enhance clinical efficiency. The leadership change not only reflects internal dynamics but also underscores how policy directions can impact drug development and patient access to new therapies. Meanwhile, strategic partnerships and market movements are reshaping industry dynamics. Pfizer and Arvinas have teamed up with Rigel Pharmaceuticals in a deal spotlighting targeted breast cancer therapies. With an upfront payment of $85 million for licensing Veppanu and potential milestone payments up to $320 million, this alliance strengthens Pfizer's oncology portfolio amid a growing focus on precision medicine. In contrast, Bayer's Eylea faces a 24% sales decline due to biosimilar competition, illustrating a broader challenge for companies dependent on established biologics. This trend highlights the necessity for innovation within ophthalmic treatments to maintain market position. Alkermes marks a significant milestone as its drug Lumryz successfully meets phase 3 trial endpoints for a rare sleep disorder. Following its acquisition of Avadel Pharmaceuticals, Alkermes is poised to expand its sleep disorder treatment offerings, providing new options where few alternatives exist. Cross-border collaborations are also gaining traction. Bristol Myers Squibb's $15 billion partnership with Hengrui Pharma leverages China's rapid R&D capabilities to advance 13 early-stage programs. Such alliances exemplify how global pharmaceutical giants are tapping into emerging markets to accelerate development timelines and enrich research pipelines. Regulatory efforts are evolving too, with the European Union pushing initiatives to enhance manufacturing autonomy and mitigate drug shortages within member states. This move addresses supply chain vulnerabilities exposed by recent global disruptions, aiming to secure critical medicine supplies through increased local production. AstraZeneca's challenges with immunogenicity issues in their endocrine disorder treatment underscore ongoing hurdles in biologics development. Despite significant investment, the molecule fell short against competitors like Ascendis Pharma's Yorvipath, highlighting the complexities of overcoming immune responses in therapeutic efficacy. Roche has achieved European approval for its second Alzheimer's disease test in collaboration with Eli Lilly, advancing diagnostic capabilities for this challenging condition. Earlier diagnosis can significantly impact treatment outcomes, marking a step forward in managing Alzheimer's disease effectively. Boehringer Ingelheim's €407 million investment in Immunitas Therapeutics demonstrates commitment to chronic inflammatory and autoimmune diseases. The focus on first-in-class biologics aligns with broader trends targeting unmet medical needs through innovative approaches. As we delve deeper into scientific advancements, Inhibrx Biosciences' phase 2 trial results offer promising developments in oncology treatment. Their combSupport the show

Moments after recording this episode of The Weekly, FDA Commissioner Marty Makary announced his resignation. Reports first circulated last Friday that President Donald Trump had signed off on his ouster. The president initially denied this account, originally from The Wall Street Journal, on Saturday morning, but appears to have now confirmed the plan. This confusion underscores a key theme in Robert F. Kennedy Jr.'s health department: lack of transparency and clear communication. Makary's exit also highlights the high level of senior leadership turnover across the Department of Health and Human Services. With Makary is on his way out, the FDA will reportedly be helmed by an acting commissioner, Kyle Diamantas. This would also be fitting for an agency whose two key review divisions—the Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER)—are currently led by temporary directors. Meanwhile, one of Makary's key initiatives, the Commissioner's National Priority Review (CNPV) program, hit a snag last week as Sanofi has reportedly requested that the FDA remove its diabetes prevention drug Tzield from the scheme. This comes after acting CDER director Tracy Beth Høeg apparently intervened in the drug's review. And in the business realm, BioSpace kicks off our annual compensation report. Who made the most money in 2025? Was it Eli Lilly's David Ricks or Johnson & Johnson's Joaquin Duato? Read BioPharm Executive to find out. Not subscribed? Sign up here for all of BioSpace's insightful newsletters.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most compelling stories and trends shaping the industry. Daiichi Sankyo has unveiled a bold five-year business plan with an eye on rising to become a top-five global oncology leader by 2035. This ambition is driven by a $1.3 billion initiative focused on antibody-drug conjugates, or ADCs, which are targeted cancer therapies. These plans highlight a strategic emphasis on oncology and operational efficiencies designed to maintain competitive advantage in a rapidly evolving market. Meanwhile, CSL Limited faces a more challenging landscape, adjusting its revenue projections and facing a significant impairment related to its acquisition of Vifor Pharma. These financial challenges underline the risks inherent in large-scale acquisitions within the pharmaceutical sector, necessitating a reassessment of strategic priorities and investments in R&D. Regulatory developments continue to be pivotal, with Partner Therapeutics' bispecific antibody Bizengri gaining FDA national priority designation for rare bile duct cancer. This underscores the FDA's dedication to expediting critical therapies through its National Priority Pilot program, aiming to bring life-saving treatments to underserved populations quickly. However, regulatory uncertainty looms with President Donald Trump's reported plan to dismiss FDA Commissioner Marty Makary, which could impact the agency's leadership and agenda. Additionally, a Supreme Court ruling has temporarily reinstated telemedicine access to mifepristone, an abortion pill, spotlighting the ongoing debates about reproductive healthcare accessibility through telemedicine. In research news, Novo Nordisk's collaboration with an AI biotech firm marks a strategic shift aimed at rescuing its Parkinson's cell therapy program. This partnership highlights the increasing role of artificial intelligence in drug development, particularly for revitalizing stalled projects using advanced technological applications. On the clinical trial front, Inhibrx's midphase results are promising for their OX40 agonist combined with Merck's Keytruda, showing doubled response rates in cancer patients. Such advancements underscore the potential of combination therapies in oncology and are likely to draw more investment interest from major players like Merck. Amgen's investment in a quantum technology firm poised for an IPO represents another exciting frontier. The application of quantum computing in drug discovery could revolutionize computational biology by accelerating therapeutic discoveries and improving precision medicine approaches. The biotech sector is also seeing financial maneuvers with quantum tech firms planning IPOs following investments from companies like Amgen. This signals a growing interest in leveraging quantum technology for breakthroughs in drug discovery. In Alzheimer's research, a novel gene therapy study presents an innovative method for clearing amyloid plaques from mouse brains without crossing the blood-brain barrier. By sending a protective gene to the liver, researchers achieved systemic plaque clearance—an approach that could revolutionize treatment strategies if successful in human trials. A new development in diagnostics involves a blood test predicting patient responses to GLP-1 receptor agonists like Ozempic and Wegovy. As these drugs become popular for weight management, such diagnostics could optimize outcomes by identifying patients most likely to benefit. Omada Health reported a 42% revenue increase in Q1, reflecting the expanding digital health solutions market. Their collaboration with Eli Lilly's employer weight loss program indicates rising demand for comprehensive health strategies integrating pharmacotherapy and digital health platforms. Overall, thSupport the show

On today's Good Day Health Show - ON DEMAND…Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken begin with what yoga can do for your heart. Yoga improves heart health by lowering blood pressure, reducing stress, decreasing heart rate, and improving cholesterol levels, often as effectively as conventional exercise. Regular practice, including poses like Downward Dog and Tadasana (Mountain Pose), boosts circulation, reduces inflammation, and strengthens the cardiovascular system.Moving on to weight loss drugs, the weight-loss drug market is shifting toward oral, daily pills like Foundayo (orforglipron) and an oral version of Wegovy (semaglutide), following FDA approval in late 2025/early 2026. These new pills, which mimic GLP-1 hormones to curb appetite, saw over 170,000 prescriptions within three weeks of launch. Increased demand has led to a potential price war between major manufacturers Novo Nordisk and Eli Lilly, as well as a rise in state Medicaid coverage. Weight loss drugs like Wegovy and Ozempic (semaglutide) are showing significant health benefits beyond shedding pounds, including a 20% reduction in heart attacks and strokes, improved kidney health, and potential addiction reduction. These drugs, known as GLP-1 receptor agonists, act on the brain to reduce cravings and reduce inflammation.Next up, Doug and Dr. Ken address Lipoprotein(a), commonly referred to as ”L-P-little-A” and abbreviated as Lp(a), is a type of genetically inherited cholesterol particle that carries fat and cholesterol through the blood. High levels of Lp(a) significantly increase the risk of heart attack, stroke, and aortic valve disease because the particles promote plaque buildup, inflammation, and blood clots in arteries Getting your Lipoprotein(a) [Lp(a)] checked via blood test is crucial because it measures a highly genetic, "sticky" form of LDL cholesterol that standard lipid panels miss. High Lp(a) significantly increases the risk of heart disease, stroke, and aortic valve stenosis, making it a critical, independent factor in assessing your overall cardiovascular health. In other news, research and studies on the effects of soccer in youth and why certain precautions need to be addressed. New reviews and studies in 2025 and 2026 indicate that frequent soccer heading is linked to measurable, long-term declines in brain structure and cognitive function, reinforcing the need for stricter rules to protect players from subconcussive injuries. Research has highlighted that repetitive, low-level impacts—not just overt concussions—damage white matter and that rule changes curbing headers are highly effective, prompting calls for broader implementation.Shifting focus, research shows adults experiencing weekly nightmares have up to a threefold higher risk of premature death (before age 70–75) and show signs of faster biological aging. This increased mortality is linked to chronic stress and accelerated cellular aging, potentially acting as a stronger risk factor than smoking or obesity. These nightmare events have your brain believing it's real and triggering real stress responses in your body. A rare nightmare won't effect health, but constant nightmares are something to be addressed. For more on Good Day Health…Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

John, Niki and merritt assess the 2026 Met Gala in real time, providing up-to-the-minute details and analysis of all the freaks in their weird getups, in addition to discussing related topics such as future Met Gala theme ideas, the surgery that makes you Korean, what constitutes a helmet, Eli Lilly's iron grasp on your grandma, defunct social media networks, and gang? Somehow even more.Welcome to If You're Driving, Close Your Eyes, a listener-supported comedy podcast where three noble explorers chip away at the crumbling foundations of reality, five or six simultaneous topics at a time. Hosted by Niki Grayson, merritt k and John Warren, and produced by Jordan Mallory, with music by Jordan and art by Max Schwartz.Follow us on Bluesky: https://bsky.app/profile/ifyouredriving.bsky.socialSupport us on Patreon: https://www.patreon.com/ifyouredriving Hosted on Acast. See acast.com/privacy for more information.

This week on the Market Maker deals show, Anthony and Stephen break down the biggest corporate finance stories moving global markets. They unpack UniCredit's hostile takeover battle for Commerzbank and why CEO Andrea Orcel is being labelled “The Shark” as European banking consolidation heats up again. They also dive into GameStop's shocking $55bn bid for eBay, Ryan Cohen's chaotic CNBC interview, and the mechanics behind meme-stock dealmaking. Finally, they explore how Eli Lilly became one of the world's most valuable companies, why it just raised $9bn in bonds, and how pharmaceutical giants use acquisitions to defend their blockbuster drug pipelines.Whether you're aiming for banking, asset management, accounting, private equity, or advisory, this is essential insight to stay ahead of the curve.(00:00) Intro & Researcher Opportunity(03:04) UniCredit vs Commerzbank(18:50) GameStop's $55BN Bid for eBay(32:18) Eli Lilly's $9BN Bond Raise & M&A StrategyConnect with Anthony on LinkedIn Watch the CNBC interview with GameStop CEO Ryan Cohen

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into a range of significant industry updates, spotlighting scientific advancements, regulatory challenges, and strategic movements that are shaping the future of drug development and patient care. The pharmaceutical landscape is often marked by rapid changes, as evidenced by recent reports indicating President Donald Trump's plan to dismiss FDA Commissioner Marty Makary. This potential leadership change is set against a backdrop of controversies during Makary's tenure, including the rejection of Replimune's advanced melanoma therapy, RP1. This therapy was designed as an oncolytic immunotherapy using a genetically modified herpes simplex virus to target and destroy cancer cells. The FDA's rejection of RP1 ignited debate over the agency's decision-making processes, which some critics view as inconsistent and lacking transparency. Such decisions can have profound implications—delaying patient access to critical treatments and affecting company financials and market dynamics. Furthermore, internal discord at the FDA during Makary's leadership period underscores the importance of stable leadership in maintaining efficiency and fostering scientific rigor. Turning to corporate developments, Gilead Sciences has revised its first-year sales forecast for YezTugo, its long-acting PrEP injection for HIV prevention. The company now projects revenues to reach $1 billion, reflecting strong market uptake. This adjustment highlights the growing demand for innovative PrEP solutions as part of broader HIV prevention strategies. Meanwhile, Daiichi Sankyo is grappling with a $610 million profit setback due to an overextension in their manufacturing capabilities for antibody-drug conjugates (ADCs). This situation illustrates the financial risks inherent in scaling production within rapidly evolving therapeutic areas like ADCs, where balancing supply and demand remains critical. In legal news, Capricor Therapeutics has initiated a lawsuit against NS Pharma concerning a breach-of-contract over Deramiocel, a Duchenne muscular dystrophy treatment. With an FDA decision pending, this legal battle underscores the complexities of partnerships and contract compliance in advancing neuromuscular therapies. On the regulatory front, Biogen and Eisai are experiencing delays from the FDA regarding their Alzheimer's drug Leqembi. These regulatory hurdles highlight the complex processes that can impact drug rollout timelines significantly. Odyssey Therapeutics' successful $304 million IPO aims to bolster its autoimmune and inflammatory disease pipeline. This reflects robust investor interest in biotech firms with promising therapeutic candidates addressing high-need areas. In terms of market dynamics, the competition between Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo is reshaping the oral GLP-1 receptor agonist market. A newly launched weekly tracker will monitor prescription trends to provide insights into how these weight-loss solutions are impacting obesity management. Additionally, Johnson & Johnson's efforts to enhance awareness around depression treatment through public health campaigns illustrate how companies are addressing mental health challenges. Advancements in digital health continue with Tether's rollout of medical AI for mobile devices and MedAptus' operational 'command center,' highlighting ongoing innovations poised to transform healthcare delivery by enhancing efficiency and patient engagement. Strategic acquisitions remain a key theme as Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion—a move that expands Angelini's footprint into the U.S. rare neurological drug market. Similarly, Blackstone's $250 million investment in Anagram Therapeutics for cystic fibrosis enzyme replacement therapySupport the show

Bonus Episode for May 8. Financial results from pharmaceutical companies Eli Lilly, Novo Nordisk, Merck, Bristol Myers Squibb and AbbVie show strong demand continuing for weight-loss drugs and autoimmune treatments. Wall Street Journal pharma reporter Peter Loftus discusses which drugmakers have the upper hand in the race to dominate those markets.  WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

I ugens Radio Information ser vi nærmere på Novo Nordisks mytiske rivalisering med medicinalgiganten Eli Lilly, den hullede jura i det ydre rum, hvor private aktører udnytter manglen på lovgivning, og en stjernefattig Cannes-festival, hvor Hollywood har valgt at blive hjemme. --- Endnu et kapitel i den 100 år lange og »mytiske rivalisering« mellem Novo Nordisk og amerikanske Eli Lilly bliver skrevet lige nu. De to medicinalgiganter producerer medicin til de samme sygdomme, men har historisk haft forskellige værdier og forskellig risikovillighed. Hvor Novo Nordisk længe holdt fast i de »hvide kitler« og en lægefaglig tilgang til fedme som en sygdom, har Eli Lilly ageret som offensive købmænd med fokus på hurtig markedsføring og direkte onlinesalg.  Men det seneste år har tvunget Novo ud af deres forsigtige konservatisme. Efter store kursfald og leveringsproblemer har de skiftet ledelsen ud og indtaget en markant mere aggressiv stil med Super Bowl-reklamer, der promoverer slankepiller som et livsstilsprodukt. Kristian Villesen fortæller hele historien om de rivaliserende medicinalgiganters mytiske fejde.  I vores serie om den internationale retsorden forlader vi i denne uge jorden til fordel for det ydre rum, hvor både juraen og rumskrottet flyder. Vi ser på, hvordan private aktører som Elon Musk udnytter den hullede lovgivning i rummet, og hvad dét betyder for menneskehedens fælles arv. Journalist William Sass er med i studiet. Og så skal det handle og kunst og kommers. For i næste uge skydes den 79. udgave af Cannes filmfestivalen i gang, men i år bliver det uden de helt store amerikanske film og filmstjerner. Festivalen har valgt at prioritere de smallere kunstfilm – og Hollywood har valgt at blive hjemme. Men er dét mest et problem for Cannes eller for Hollywood? Og hvad siger armlægningen om filmbranchens aktuelle situation? Jeg spørger filmredaktør Christian Monggaard, der i år deltager på festivalen for 26. gang. 

Trump-backed candidates defeat most redistricting-opposed incumbents in GOP primaries. Eli Lilly unveils a further $4.5 billion investment in the LEAP District, bringing total investments in the state to over $20 billion since 2020. Governor Braun extends the gas sales tax pause for another 30 days, and includes a new pause to the state gas tax to save Hoosiers around $0.59 per gallon.

This week's guest on The PR Week podcast is Courtney Kasinger, executive director of communications at Eli Lilly and Company and jury chair for the 2026 PRWeek Healthcare Awards.  She talks about standout work from this year's awards program and other trends she's seeing in healthcare and marketing communications.  Plus the biggest marketing and communications news of the week, such as major agency acquisitions and a new role for one of the sports world's most prominent communicators. PRWeek.comTheme music provided by TRIPLE SCOOP MUSICJaymes - First One Follow us: @PRWeekUSReceive the latest industry news, insights, and special reports. Start Your Free 1-Month Trial Subscription To PRWeek Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A.M. Edition for May 6. A Journal investigation finds China is supplying Russia and Iran with drone factories. WSJ senior correspondent Josh Chin explains how Chinese companies are managing to circumvent U.S. sanctions. Plus, Samsung joins the trillion dollar club amid relentless demand for AI memory chips. And weight-loss drug giant Novo Nordisk surprises with strong sales even as competition with Eli Lilly continues to weigh on growth. Daniel Bach hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Markets have roared back at record speed, big tech earnings are still doing ridiculous things, and investors are once again being reminded why staying invested matters. Bryce and Alec unpack the Iran-driven market wobble, Australia's rate rise and looming budget, before diving into results from Alphabet, Berkshire Hathaway and Eli Lilly, plus the long-term numbers showing shares can absolutely hold their own against property.In this episode: 00:00 — The fastest market rebound ever03:59 — Iran conflict, oil and market implications05:49 — RBA lifts rates back to 4.35%07:34 — Budget watch: housing, tax and spending cuts13:08 — Earnings season and big tech's huge numbers15:18 — Alphabet smashes expectations19:14 — Berkshire Hathaway's record cash pile22:10 — Eli Lilly Earnings Results24:21 — Shares vs property: the long-term numbersStocks and ETFs mentioned: Apple (NASDAQ: AAPL), Alphabet (NASDAQ: GOOGL), Microsoft (NASDAQ: MSFT), Meta (NASDAQ: META), Amazon (NASDAQ: AMZN), Reddit (NYSE: RDDT), Eli Lilly (NYSE: LLY), Berkshire Hathaway (NYSE: BRK.B), Spotify (NYSE: SPOT), Duolingo (NASDAQ: DUOL), Commonwealth Bank (ASX: CBA), Telstra (ASX: TLS)Links to resources mentioned: Pivot Wealth Study - https://pivotwealth.com.au/blog/long-term-investment-returns-australia/Shane Oliver's (AMP) Study - https://www.amp.com.au/resources/insights-hub/is-the-long-underperformance-versus-global-shares-over———Want to get involved in the podcast? Record a voice note or send us a messageAnd come and join the conversation in the Equity Mates Facebook Discussion Group.———Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing – we've got you covered.Keep up with the news moving markets with our daily newsletter and podcast (Apple | Spotify)We're particularly excited to share our latest show: Basis PointsListen to the podcast (Apple | Spotify)Watch on YouTubeRead the monthly email———Looking for some of our favourite research tools?Download our free Basics of ETF handbookOr our free 4-step stock checklistFind company information on TIKRResearch reports from Good ResearchTrack your portfolio with Sharesight———In the spirit of reconciliation, Equity Mates Media and the hosts of Equity Mates Investing acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander people today.———Equity Mates Investing is a product of Equity Mates Media. Hosted on Acast. See acast.com/privacy for more information.

The Devil Wears Prada vs. the Met Gala… One is “sold out,” the other is a “sell-out”Streaks, leaderboards, & “Max Badges”... New rule for Disney employees? Use AI #PromptPressureThe world's most popular drug of all-time is now GLP-1… And Eli Lilly is winning the race.Plus, Venmo is up for sale… who should buy it?$PYPL $DIS $LLYNEWSLETTER:https://tboypod.com/newsletter OUR 2ND SHOW:Want more business storytelling from us? Check our weekly deepdive show, The Best Idea Yet: The untold origin story of the products you're obsessed with. Listen for free to The Best Idea Yet: https://wondery.com/links/the-best-idea-yet/NEW LISTENERSFill out our 2 minute survey: https://qualtricsxm88y5r986q.qualtrics.com/jfe/form/SV_dp1FDYiJgt6lHy6GET ON THE POD: Submit a shoutout or fact: https://tboypod.com/shoutouts SOCIALS:Instagram: https://www.instagram.com/tboypod TikTok: https://www.tiktok.com/@tboypodYouTube: https://www.youtube.com/@tboypod Linkedin (Nick): https://www.linkedin.com/in/nicolas-martell/Linkedin (Jack): https://www.linkedin.com/in/jack-crivici-kramer/Anything else: https://tboypod.com/ About Us: The daily pop-biz news show making today's top stories your business. Formerly known as Robinhood Snacks, The Best One Yet is hosted by Jack Crivici-Kramer & Nick Martell. Hosted on Acast. See acast.com/privacy for more information.

Markets push through a busy earnings slate as investors weigh strong results and rising expectations. Dan Skelly, Managing Director at Morgan Stanley Wealth Management, explains why the bar for earnings beats remains high and what it means for stocks from here. Instant analysis and reaction to Palantir earnings with Gil Luria of D.A. Davidson. Dennis Geiger of UBS looks ahead to McDonald's earnings and explains why he sees an attractive risk reward setup. Our Angelica Peebles reports on the next phase of the weight loss drug story as pills from Eli Lilly and Novo Nordisk begin to reshape the GLP-1 market and expand demand. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rural Health News is a weekly segment of Rural Health Today, a podcast by Hillsdale Hospital. News sources for this episode: Gary L. Roth, DO, “Fact Check: Drug Pricing Savings Are the Lifeline to Community Healthcare Services,” April 30, 2026, https://www.mha.org/newsroom/fact-check-drug-pricing-savings-are-the-lifeline-to-community-healthcare-services/, Michigan Health and Hospital Association.  American Hospital Association, “AHA urges HRSA to act as Eli Lilly threatens 340B discounts over claims data submission policy,” April 27, 2026, https://www.aha.org/news/headline/2026-04-27-aha-urges-hrsa-act-eli-lilly-threatens-340b-discounts-over-claims-data-submission-policy.  American Hospital Association, “Washington Post publishes AHA letter in response to anti-340B editorial,” April 22, 2025, https://www.aha.org/news/headline/2026-04-22-washington-post-publishes-aha-letter-response-anti-340b-editorial. Jennifer Wessel, JD, MPH, “Commercial Insurers' Payments to Hospitals Closer to Medicare Rates in Arkansas Than in Any Other State,” May 15, 2024, https://achi.net/newsroom/commercial-insurers-payments-to-hospitals-closer-to-medicare-rates-in-arkansas-than-in-any-other-state/, Arkansas Center for Health Improvement. Tess Vrbin, “Low reimbursement rates force Arkansas hospitals to scale back services,” April 21, 2026, https://arkansasadvocate.com/2026/04/21/low-reimbursement-rates-force-arkansas-hospitals-to-scale-back-services/, Arkansas Advocate. Rural Health Today is a production of Hillsdale Hospital in Hillsdale, Michigan and a member of the Health Podcast Network. Our host is JJ Hodshire, our producer is Kyrsten Newlon, and our audio engineer is Kenji Ulmer. Special thanks to our special guests for sharing their expertise on the show, and also to the Hillsdale Hospital marketing team. If you want to submit a question for us to answer on the podcast or learn more about Rural Health Today, visit ruralhealthtoday.com.

Home from space, the crew of the Artemis II stops by the Squawk set. Commander Reid Wiseman, Pilot Victor Glover, and Mission Specialists Christina Koch and Jeremy Hansen discuss their brave journey around the moon, the newest frontiers, the emotional and physical toll of takeoff and reentry, and handling snafus–like smoke alarms and toilet troubles–while in space. Eli Lilly CEO David Ricks discusses the drugmaker's big financial quarter in an exclusive interview. He shares the first prescription numbers of Lilly's newest GLP-1 pill, Foundayo, as well as how it differs from Zepbound and Novo Nordisk's Wegovy. Plus, Anthropic is in talks to raise funds at a $900B valuation, the Saudi Public Investment Fund will stop funding the LIV Golf League, and Jerome Powell will remain on the Fed's Board of Governors after his time as Chairman ends.    Steve Liesman - 3:17 Angelica Peebles & David Ricks - 17:12 Artemis II Crew - 32:06   In this episode: Artemis Crew, @NASAArtemis Steve Liesman, @steveliesman Angelica Peebles, @angelicapeebles Joe Kernen, @JoeSquawk Andrew Ross Sorkin, @andrewrsorkin Cameron Costa, @CameronCostaNY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On the last trading day of the month, Carl Quintanilla, Jim Cramer and David Faber led off the show with market reaction to quarterly results from four of the "Magnificent 7": Alphabet, Amazon, Meta and Microsoft. The anchors explored which of those tech giants are best  positioned in the AI race. Hear what top executives from the four companies said on their respective earnings calls about capex strategy. Also in focus: Shares of Caterpillar and Eli Lilly jump on earnings beats, Nvidia and the AI trade, President Trump lauds the Intel rally as the stock more than doubles in April, Elon Musk back on the stand at the OpenAI trial, PCE — the Fed's preferred inflation gauge — posts its biggest gain in almost three years in wake of the Iran war. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We discuss what's at stake from Apple's big report in Overtime with Alger's Dan Chung, Big Technology's Alex Kantrowitz and Wedbush's Dan Ives. Plus, one of the nation's top financial advisors – Chris Toomey of Morgan Stanley – tells us how he is advising his clients right now. And, we drill down on the massive move in Eli Lilly ahead of Amgen's numbers. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Federal Reserve held interest rates steady at 3.5%–3.75%, but the bigger story may be what comes next. Powell announced he plans to remain on the Federal Reserve Board as a governor after his term ends—an unusual move that limits a potential board vacancy and keeps his influence in play. Lance Roberts & Michael Lebowitz examine what this means for monetary policy, market expectations, and the timing of future rate cuts. Key topics include: 0:00 - INTRO 1:02 - Closing Out April, Moving Into May: earnings season winding down 3:52 - Eli Lilly & GLP-1 4:21 - No Change in Fed Stance & Oil Prices 6:04 - Market Consolidation Continues 9:56 - Mrs. Roberts Moderates & Likes for Lebo 11:47 - Mag-4 Earnings Review 16:16 - Eli Lilly & Myriad Applications for GLP-1 19:13 - Most Uneventful Eventful Fed Meeting 23:22 - Office Politics at The Fed 26:01 - The Hawkish Take is the Correct One 27:41 - What Really Drives Inflation (not car insurance) 31:47 - Inflation Varies by Location 33:15 - The Fed is Stuck 34:59 - Oil Futures Pricing & the "Sweet Spot" 36:47 - Earnings & Profit Margins - Where's the Risk? 39:08 - Caterpillar Earnings & Data Center Construction Hosted by RIA Advisors Chief Investment Strategist, Lance Roberts, CIO, w Senior Investment Advisor, Danny Ratliff, CFP Produced by Brent Clanton, Executive Producer ------- Do you enjoy our content? Rate us on Google: https://bit.ly/4b9JtEo ------- Watch Today's Full Video on our YouTube Channel: https://youtube.com/live/oYQSPI-_BqE?feature=share ------- Watch today's "Before the Bell" feature, "Market Stalls as Risks Build," here: https://youtu.be/SSzwq4AG2-0 ------- Watch our previous show, "Q&A Wednesday: Markets & Your Money ," https://youtube.com/live/xzazFr20EOE ------- * REGISTER for our next Candid Coffee, Saturday, May 16: "Financial Organization Made Simple:" https://streamyard.com/watch/SA6aj2aMdMhf -------- Resources Mentioned in Today's Show: "Hormuz: Why Markets Are Shrugging Off The Oil Shock" https://realinvestmentadvice.com/resources/blog/hormuz-why-markets-are-shrugging-off-the-oil-shock/ "The Dollar's Funeral Keeps Getting Rescheduled" https://realinvestmentadvice.com/resources/blog/the-dollars-funeral-keeps-getting-rescheduled/ ------- Download Lance's Latest e-book, "Laws of Money & Wealth:"https://realinvestmentadvice.com/ria-e-guide-library/ -------- SUBSCRIBE to The Real Investment Show here: http://www.youtube.com/c/TheRealInvestmentShow -------- Visit our Site: https://www.realinvestmentadvice.com Contact Us: 1-855-RIA-PLAN -------- Subscribe to SimpleVisor: https://www.simplevisor.com/register-new -------- Connect with us on social: https://twitter.com/RealInvAdvice https://twitter.com/LanceRoberts https://www.facebook.com/RealInvestmentAdvice/ https://www.linkedin.com/in/realinvestmentadvice/ #StockMarket #MarketOutlook #InvestingStrategy #EarningsSeason #RiskManagement #FederalReserve #InterestRates #JeromePowell #MonetaryPolicy

We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of the numbers that were so incredible to hear. This video analyzes Eli Lilly's Q1 2026 earnings call, discussing key products like eloralintide, brenipatide, and retatrutide, providing essential finance news and stock market news for those tracking pharmaceutical companies. The presenter highlights the strong start of Foundayo's U.S. launch and reviews the Lilly Select Pipeline, touching upon the U.S. Incretin Analogs Market and broader healthcare industry trends.WAYS TO SUPPORT MY WORK ⬇️http://www.otplinks.com